Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two-Decade Old US Interstate Compounding Provision Stayed For More Comments

Executive Summary

Responding to court ruling, US FDA will explore what it will cost compounding pharmacies to submit to increased state restrictions and oversight of out-of-state compounding quality under a standard MOU that Congress required decades ago.

You may also be interested in...



US FDA Must Assess Business Impact Of Final Interstate Compounding MOU, Court Rules

Summary judgment puts 20-year-old effort to define ‘inordinate’ out-of-state drug compounding back on slow track.

A Lesson on Outsourcing: The NECC Fungal Meningitis Outbreak

US FDA Training Up Inspectorate To Oversee Quality Of Novel Manufacturing Technologies

Agency is hiring contractor to identify gaps in the ability of inspectors, investigators and compliance officers to oversee manufacturing quality in the context of new and emerging technologies – and to identify organizations that could fill the gaps through training.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel